Clinical Trials Logo

Filter by:
NCT ID: NCT06299410 Recruiting - Healthy Volunteers Clinical Trials

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

Start date: April 11, 2024
Phase: Phase 1
Study type: Interventional

The study will be conducted as an open-label and single-center study to evaluate the occupancy of ITI-1284 to the dopamine D2 receptor in healthy subjects. Subjects will enroll in one of the 2 cohorts, will have a baseline PET/CT scan, will receive a single dose of ITI-1284, and undergo one postdose PET/CT scan.

NCT ID: NCT06299332 Recruiting - Clinical trials for Erectile Dysfunction

Safety and Efficacy of Bi-Polar Radiofrequency for the Treatment of Erectile Dysfunction

Start date: June 23, 2023
Phase: N/A
Study type: Interventional

The goal of this prospective pilot study is to learn about the Safety and Efficacy of Radiofrequency (RF) for the Treatment of Erectile Dysfunction. This research study is trying to determine if RF therapy is safe and effective in patients with symptoms of erectile dysfunction (ED).

NCT ID: NCT06299228 Recruiting - Clinical trials for Distal Radius Fractures

Is Sensorimotor Training Effective Following a Distal Radius Fracture?

Start date: April 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the short-term outcomes of individuals who have surgery (volar plate) for a wrist (distal radius) fracture who have routine hand therapy treatment versus routine hand therapy treatment and sensorimotor activities. Individuals who meet inclusion criteria at the facilities collecting data will be invited to participate. If they agree to participate, they will randomly and blindly (via concealed envelopes) be assigned to the control (routine treatment) or the sensorimotor treatment group. Data collection will occur at 3- and 6-weeks post initiation of skilled therapy and will include measurement of joint position sense, function via the Patient Rated Wrist and Hand, pain via the Numeric Pain Rating Scale, and range of motion at the digits and wrist.

NCT ID: NCT06299163 Recruiting - Endometrial Cancer Clinical Trials

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

NCT ID: NCT06298981 Recruiting - Clinical trials for Pulse Rate and Breathing Rate

Pulse Rate and Breathing Rate Accuracy

Start date: February 12, 2024
Phase:
Study type: Observational

The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.

NCT ID: NCT06298721 Recruiting - Surgery Clinical Trials

Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes

Start date: March 12, 2024
Phase: N/A
Study type: Interventional

This study is a randomized controlled trial to assess whether the implementation of a TKA Personalized Outcome Prediction Tool to set expectation, in addition to targeted interventions to address patients with poor baseline mental health and poor physical function, improves satisfaction at 1-year (when compared to standard of care).

NCT ID: NCT06298552 Recruiting - Clinical trials for Generalized Myasthenia Gravis

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

ADAPT SERON
Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). Other objectives are to assess long-term efficacy, safety, and tolerability of efgartigimod. Study will consist of: - Screening - Part A: participants will be randomized to receive either efgartigimod IV or placebo - Part B: participants completing part A will receive open-label efgartigimod IV

NCT ID: NCT06298409 Recruiting - Clinical trials for Small Intestinal Bacterial Overgrowth

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

Start date: February 15, 2024
Phase:
Study type: Observational

We will sample intestinal microbiota using a microbiome sampling capsule in patients with Small Intestinal Bacterial Overgrowth (SIBO)

NCT ID: NCT06297993 Recruiting - PSC Clinical Trials

Adult Patients With Primary Sclerosing Cholangitis

WIND-PSC
Start date: May 6, 2024
Phase:
Study type: Observational

Develop an appropriate real-world data comparator cohort to support the design, execution, and serve as an external control for interventional clinical trials in PSC.

NCT ID: NCT06297980 Recruiting - Type 1 Diabetes Clinical Trials

Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

MERIT
Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and food intake to ameliorate cycle-related glycemic variability. A secondary aim is to examine how the menstrual cycle and use of hormonal birth control impact patient-reported outcomes and glycemic responses to physical activity.